Expanding Medication Assisted Treatment for Opioid Use Disorders in the Context of the SAMHSA Opioid STR Grants (R21/R33)
Application: Jun 20, 2017
This program provides grants to test approaches for expanding medication assisted treatment (MAT) for opioid use (OUD) disorder in the general healthcare sector or linking individuals who receive naloxone for the reversal of overdose to MAT. Projects must be designed in the context of state plans for use of the funds authorized under the 21st Century Cures Act.
Projects must meet the criteria listed below.
- Projects must leverage an opportunity made available by funding that states receive under SAMHSA TI-17-04.
- Project teams must include relevant single state agency staff as key personnel.
- Projects must be designed to generate causal inferences on the effects of approaches to expanding MAT using FDA-approved OUD medications in the general healthcare sector or linking those treated with naloxone to MAT on outcomes including drug use and/or overdose deaths; length of time on medication, dropout, time to relapse; and at least one other physical or mental health or health-related outcome.
Examples of research topics are provided in the application instructions.
Eligible organizations include:
- Higher education institutions
- Government organizations
- Independent school districts
- Public Housing Authorities/Indian Housing Authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
R21 exploratory/developmental phase I grants may not exceed $200,000, with a project period of 1 year.
R33 phase II grants direct costs must not exceed $500,000 in any year. The maximum project period for R33 grants is 3 years.
NIH intends to commit $2,000,000 to fund 3-4 awards.
For complete information about funding programs, including your application status, please contact funders directly. Summaries are provided for your convenience only. RHIhub does not take part in application processes or monitor application status.